Skip to content
ClinCalc Pro
Menu
Calculators Drugs Pathways AI Dx Donate Get the App
EGFR/MET Bispecific Antibody (Specialist Oncology Drug)

Amivantamab

Brand names: Rybrevant

Amivantamab is a bispecific monoclonal antibody targeting EGFR and MET, used in certain non-small-cell lung cancers, notably those with EGFR exon 20 insertion mutations.

Dosing — being independently re-sourced

ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.

Clinical monograph

How it works

It binds both EGFR and MET, blocking ligand-driven signalling and promoting receptor degradation and immune-cell-mediated clearance of tumour cells.

Prescribing in practice

  • Infusion-related reactions are common, particularly with the first infusion, so split initial dosing as directed, give premedication, and have measures ready to manage reactions.
  • Given by intravenous infusion under specialist oncology supervision.
  • Interstitial lung disease/pneumonitis and significant skin and nail toxicity can occur and may require dose modification.

Monitoring

Monitor for infusion-related reactions, dermatological and nail toxicity, new or worsening respiratory symptoms suggesting pneumonitis, and venous thromboembolism.

Counselling the patient

  • First infusions are given slowly and split over days to reduce reactions; report any chills, breathlessness, or dizziness during infusion.
  • Report new cough or breathlessness, and use sun protection and skin care for rash.
  • Report painful or infected skin around the nails.

Evidence & guidelines

Use in EGFR exon 20 insertion NSCLC is supported by trial data and relevant regulatory approvals; consult the SPC and current prescribing references.

Reference: NICE TA854 (Amivantamab for EGFR exon 20 insertion NSCLC, 2023); CHRYSALIS trial (J Clin Oncol 2021); ESMO NSCLC Guidelines; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.

Calculators
Pathways